Garetosmab-grts

Brand names: Pasatru · Active ingredient: Garetosmab

In short: PASATRU is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP).

Forms & strengthsInjection: 300 mg/5 mL (60 mg/mL) clear to slightly opalescent, colorless to pale yellow solution in a single-dose vial.
LabelRegeneron Pharmaceuticals, Inc.
Label updatedAug 24, 2026

What is Garetosmab-grts used for?

PASATRU is indicated to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP).

Garetosmab-grts dosage

Verify that females of reproductive potential are not pregnant prior to initiating PASATRU [see Contraindications (4), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].

The recommended starting dosage of PASATRU is 10 mg/kg administered as an intravenous infusion over 60 minutes once every 4 weeks. The dosage of PASATRU may be decreased to 3 mg/kg administered as an intravenous infusion over 60 minutes once every 4 weeks if 10 mg/kg is not tolerated.

If a dose of PASATRU is missed, administer the dose as soon as possible. Thereafter, PASATRU should be scheduled once every 4 weeks from the date of the last dose.

Preparation

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. PASATRU is a clear to slightly opalescent, colorless to pale yellow solution. Discard the vial if the solution is cloudy, discolored, or contains particulate matter.

Each vial is intended for one-time use only.

Do not shake the vial. Withdraw the required volume from the vial(s) of PASATRU and transfer into an intravenous infusion bag [polyvinyl chloride (PVC), polyolefin (PO), or ethyl vinyl acetate (EVA)] containing a minimum of 50 mL and a maximum of 100 mL of 5% Dextrose Injection, USP to prepare a diluted solution with a final concentration ranging from 0.9 mg/mL to 25 mg/mL.

Mix the diluted solution by gentle inversion. Do not shake the solution.

Discard any unused portion left in the vial.

Storage of Infusion Solution

Use diluted PASATRU immediately. If not used immediately, store the diluted solution refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 24 hours or at room temperature up to 25°C (77°F) for no more than 16 hours from the time of preparation to the start of infusion.

Do not freeze the diluted solution.

Administration

If refrigerated, allow the diluted solution to come to room temperature prior to administration.

Administer PASATRU diluted solution by intravenous infusion over 60 minutes using an infusion set constructed of PVC, polyethylene (PE)-lined PVC, or polyurethane (PU). A sterile, in-line or add-on, 0.2-micron to 5-micron polyethersulfone (PES) or polyamide (PA) filter is recommended.

PASATRU should be administered using an infusion pump to control the rate of infusion.

Upon completion of the PASATRU infusion, flush the infusion line with an adequate volume of sterile 5% Dextrose Injection, USP to ensure that the entire contents of the infusion bag are administered.

Do not mix other drugs with PASATRU or administer other drugs concomitantly via the same infusion line.

How to take Garetosmab-grts — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Embryo-Fetal Toxicity

PASATRU can cause fetal harm and is contraindicated during pregnancy. Advise patients to immediately stop PASATRU and contact their healthcare provider if pregnancy occurs during treatment [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1)].

Advise females of reproductive potential to use effective contraception during treatment with PASATRU and for 6 months after the last dose .

Skin and Soft Tissue Infections

Advise patients that PASATRU may cause abscesses and cellulitis and to report signs or symptoms of infection, such as erythema, pain, swelling, or fever, to their healthcare provider .

Epistaxis

Advise patients to seek medical attention if they experience epistaxis that is severe, prolonged (e.g., lasting more than 20 minutes) and does not resolve with standard first-aid measures .

Lactation

Advise patients not to breastfeed during treatment with PASATRU and for 6 months after the last dose .

Warnings & precautions

Do not take this medicine if: PASATRU is contraindicated during pregnancy. PASATRU can cause fetal harm when administered to a pregnant woman .

PASATRU is contraindicated during pregnancy. Based on its mechanism of action and findings from animal reproduction studies, PASATRU can cause fetal harm when administered to a pregnant woman . Intravenous administration of garetosmab-grts to pregnant cynomolgus monkeys resulted in embryo-fetal toxicity, infant mortality, and post-natal malformations at exposures equivalent to or higher than those in patients at the recommended human doses of PASATRU 10 mg/kg or 3 mg/kg every 4 weeks, respectively.

For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment with PASATRU and for 6 months after the last dose. Advise the patient to discontinue PASATRU immediately if pregnancy occurs during treatment and to contact their healthcare provider .

Skin and soft tissue infections requiring treatment and/or hospitalization, including abscesses and cellulitis , have occurred in patients receiving PASATRU in clinical trials.

Advise patients to report signs or symptoms of skin infection, including erythema, pain, swelling, or fever, and to seek medical attention if these occur.

Spontaneous epistaxis, including serious cases requiring medical intervention, has been reported in patients receiving PASATRU. In clinical trials in the FOP population, one serious case of spontaneous epistaxis occurred that required hospitalization for nasal packing and application of a clotting agent.

Advise patients to seek medical attention if they experience epistaxis that is severe, prolonged (e.g., lasting more than 20 minutes) and does not resolve with standard first-aid measures.

Garetosmab-grts side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Skin and Soft Tissue Infections

Epistaxis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PASATRU was evaluated in a randomized, double-blind, parallel-group, multicenter, placebo-controlled trial that enrolled a total of 63 adults with FOP. Patients received placebo or PASATRU 10 mg/kg or 3 mg/kg every 4 weeks in the 56-week double-blind treatment period then continued their originally assigned treatment in a double-blind extension phase .

Table 1 summarizes the adverse reactions occurring in ≥10% of patients treated with PASATRU (10 mg/kg or 3 mg/kg) every 4 weeks and more frequently than placebo through Week 56.

Adverse Reaction | Placebo | PASATRU 10 mg/kg every 4 weeks | PASATRU 3 mg/kg every 4 weeks

N=21 n (%) | N=23 n (%) | N=19 n (%)

AbscessAbscess includes abscess, abscess limb, subcutaneous abscess, and tooth abscess. | 2 (10%) | 8 (35%) | 2 (11%)

Acne | 2 (10%) | 7 (30%) | 3 (16%)

Increased hair growthIncreased hair growth includes hirsutism, hypertrichosis, hair growth abnormal, and hair disorder. …

About this medicine

Garetosmab-grts is an activin signaling inhibitor. Garetosmab-grts is a human IgG4 monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. Garetosmab-grts has an approximate molecular weight of 146 kDa.

PASATRU (garetosmab-grts) injection is a sterile, preservative-free solution for intravenous use. The solution is clear to slightly opalescent, colorless to pale yellow with a pH of 6.3.

Each PASATRU 300 mg/5 mL vial contains 300 mg of garetosmab-grts. Each mL contains 60 mg of garetosmab-grts, arginine hydrochloride (14.7 mg), histidine (1 mg), L-histidine hydrochloride monohydrate (0.7 mg), polysorbate 20 (0.5 mg), sucrose (50 mg), and Water for Injection, USP.

How it works: FOP is caused by gain-of-function mutations in the intracellular domain of activin receptor type 1 (ACVR1, also known as ALK2), a bone morphogenetic protein (BMP) type I receptor that is expressed in many tissues, including skeletal muscle and cartilage. In patients with FOP, mutant ACVR1 is activated by activin A resulting in heterotopic ossification. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0d5cec96-b02b-4f1d-bc66-51e62ce04e3c. Read the full official label on DailyMed.